OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 31
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 51
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 51
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Gail Hayward, Ly‐Mee Yu, Paul Little, et al.
Journal of Infection (2024) Vol. 88, Iss. 4, pp. 106130-106130
Open Access | Times Cited: 13
Gail Hayward, Ly‐Mee Yu, Paul Little, et al.
Journal of Infection (2024) Vol. 88, Iss. 4, pp. 106130-106130
Open Access | Times Cited: 13
Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents
Marwa Almulhim, Abdolmajid Ghasemian, Mojtaba Memariani, et al.
Molecular Diversity (2025)
Open Access | Times Cited: 1
Marwa Almulhim, Abdolmajid Ghasemian, Mojtaba Memariani, et al.
Molecular Diversity (2025)
Open Access | Times Cited: 1
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Zhilong Song, Senyuan Shi, Yongli Zhang
Heliyon (2024) Vol. 10, Iss. 6, pp. e27647-e27647
Open Access | Times Cited: 7
Zhilong Song, Senyuan Shi, Yongli Zhang
Heliyon (2024) Vol. 10, Iss. 6, pp. e27647-e27647
Open Access | Times Cited: 7
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Fatma Haddad, Ghadeer Dokmak, Rafik Karaman
Life (2022) Vol. 12, Iss. 11, pp. 1758-1758
Open Access | Times Cited: 22
Fatma Haddad, Ghadeer Dokmak, Rafik Karaman
Life (2022) Vol. 12, Iss. 11, pp. 1758-1758
Open Access | Times Cited: 22
Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?
Wolfgang Löscher
Epilepsia (2023) Vol. 64, Iss. 3, pp. 553-566
Open Access | Times Cited: 13
Wolfgang Löscher
Epilepsia (2023) Vol. 64, Iss. 3, pp. 553-566
Open Access | Times Cited: 13
COVID-19 Vaccine Acceptance and Hesitancy among Healthcare Workers in Lusaka, Zambia; Findings and Implications for the Future
Steward Mudenda, Victor Daka, Scott Kaba Matafwali, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1350-1350
Open Access | Times Cited: 13
Steward Mudenda, Victor Daka, Scott Kaba Matafwali, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1350-1350
Open Access | Times Cited: 13
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity
Sunil J. Wimalawansa
Heliyon (2024) Vol. 10, Iss. 15, pp. e34691-e34691
Open Access | Times Cited: 4
Sunil J. Wimalawansa
Heliyon (2024) Vol. 10, Iss. 15, pp. e34691-e34691
Open Access | Times Cited: 4
Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy
Baneet Kaur, Cyril Blavo, Mayur Parmar
Cureus (2024)
Open Access | Times Cited: 3
Baneet Kaur, Cyril Blavo, Mayur Parmar
Cureus (2024)
Open Access | Times Cited: 3
A beta regression analysis of COVID-19 mortality in Brazil
Francisco Cribari‐Neto
Infectious Disease Modelling (2023) Vol. 8, Iss. 2, pp. 309-317
Open Access | Times Cited: 8
Francisco Cribari‐Neto
Infectious Disease Modelling (2023) Vol. 8, Iss. 2, pp. 309-317
Open Access | Times Cited: 8
COVID-19 Case Management Outcomes Amongst Diabetes and Hypertensive Patients in the United Arab Emirates: A Prospective Study
Aysha Alkhemeiri, Shaikha Al Zaabi, Lakshmanan Jeyaseelan, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 23, pp. 15967-15967
Open Access | Times Cited: 8
Aysha Alkhemeiri, Shaikha Al Zaabi, Lakshmanan Jeyaseelan, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 23, pp. 15967-15967
Open Access | Times Cited: 8
A Twisting Tale of Misinformation: Should Ivermectin be Approved as a Treatment for COVID-19 Disease?
Arman Shafiee, Mohammad Mobin Teymouri Athar, Sayed‐Hamidreza Mozhgani
Future Virology (2023) Vol. 18, Iss. 3, pp. 137-139
Open Access | Times Cited: 4
Arman Shafiee, Mohammad Mobin Teymouri Athar, Sayed‐Hamidreza Mozhgani
Future Virology (2023) Vol. 18, Iss. 3, pp. 137-139
Open Access | Times Cited: 4
An evidence double standard for pharmacological versus non-pharmacological interventions: Lessons from the COVID-19 pandemic
Tracy Beth Høeg, V. Kanti Prasad
Contemporary Clinical Trials Communications (2023) Vol. 33, pp. 101108-101108
Open Access | Times Cited: 4
Tracy Beth Høeg, V. Kanti Prasad
Contemporary Clinical Trials Communications (2023) Vol. 33, pp. 101108-101108
Open Access | Times Cited: 4
Awareness and Practices towards Vaccinating Their Children against COVID-19: A Cross-Sectional Study among Pakistani Parents
Zain Ul Harmain, Noorah A. Alkubaisi, Muhammad Hasnain, et al.
Healthcare (2023) Vol. 11, Iss. 17, pp. 2378-2378
Open Access | Times Cited: 4
Zain Ul Harmain, Noorah A. Alkubaisi, Muhammad Hasnain, et al.
Healthcare (2023) Vol. 11, Iss. 17, pp. 2378-2378
Open Access | Times Cited: 4
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials
Paulo Ricardo Martins‐Filho, Edmundo Marques do Nascimento-Júnior, José Antônio Barreto-Alves, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 11, pp. 1813-1821
Open Access | Times Cited: 7
Paulo Ricardo Martins‐Filho, Edmundo Marques do Nascimento-Júnior, José Antônio Barreto-Alves, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 11, pp. 1813-1821
Open Access | Times Cited: 7
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic
Manuel Castillejos‐López, Luz María Torres‐Espíndola, Juan Carlos Huerta-Cruz, et al.
Life (2022) Vol. 12, Iss. 9, pp. 1384-1384
Open Access | Times Cited: 7
Manuel Castillejos‐López, Luz María Torres‐Espíndola, Juan Carlos Huerta-Cruz, et al.
Life (2022) Vol. 12, Iss. 9, pp. 1384-1384
Open Access | Times Cited: 7
Hesitação vacinal na Covid-19: um estudo qualitativo
Ana Carolina da Silva Corrêa, Andrea Souza Rodrigues Nogueira, Millena Kellen Sousa Carvalho, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 4, pp. e72337-e72337
Open Access
Ana Carolina da Silva Corrêa, Andrea Souza Rodrigues Nogueira, Millena Kellen Sousa Carvalho, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 4, pp. e72337-e72337
Open Access
MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus
Kenya DeBarros, Mahfuz Khan, Morgan Coleman, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1433-1433
Open Access
Kenya DeBarros, Mahfuz Khan, Morgan Coleman, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1433-1433
Open Access
Samesweringsteorieë en vals nuus in leserskommentaar op nuusberigte van Maroela Media tydens die COVID-19-pandemie
Burgert Senekal
Tydskrif vir Geesteswetenskappe (2023) Vol. 63, Iss. 4, pp. 921-945
Open Access | Times Cited: 1
Burgert Senekal
Tydskrif vir Geesteswetenskappe (2023) Vol. 63, Iss. 4, pp. 921-945
Open Access | Times Cited: 1
Green Chemistry Considerations in the Synthesis of Nirmatrelvir, the Active Pharmaceutical Ingredient (API) in Paxlovid™
Berkeley W. Cue, David A. Daggett
Elsevier eBooks (2024)
Closed Access
Berkeley W. Cue, David A. Daggett
Elsevier eBooks (2024)
Closed Access
COVID-19 and male fertility
Mohammad Reza Fadaei, Mohammad Mahdi Dabaghi, Mohammad Saleh Fadaei, et al.
Elsevier eBooks (2024), pp. 353-364
Closed Access
Mohammad Reza Fadaei, Mohammad Mahdi Dabaghi, Mohammad Saleh Fadaei, et al.
Elsevier eBooks (2024), pp. 353-364
Closed Access
Mind the Guardrails: Epistemic Trespassing and Apt Deference
Neil Levy, R. S. Varley
Social Epistemology (2024), pp. 1-17
Open Access
Neil Levy, R. S. Varley
Social Epistemology (2024), pp. 1-17
Open Access
Integrating Computational Approaches from Non-synonymous Sequence Variations to Molecular Structure for Drug Repositioning Targeting the SARS-CoV-2 Spike Protein
Leon S. C. Costa, Isabella Alvim Guedes, Haron C. Fanticelli, et al.
Springer eBooks (2024), pp. 223-254
Closed Access
Leon S. C. Costa, Isabella Alvim Guedes, Haron C. Fanticelli, et al.
Springer eBooks (2024), pp. 223-254
Closed Access
Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients
Jorge García-Méndez, Luis E. Fernández-Garza, Karen Vallejo-Oviedo, et al.
Cureus (2024)
Open Access
Jorge García-Méndez, Luis E. Fernández-Garza, Karen Vallejo-Oviedo, et al.
Cureus (2024)
Open Access
An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
Phahol Sarojvisut, Anucha Apisarnthanarak, Kittiya Jantarathaneewat, et al.
Infection and Chemotherapy (2022) Vol. 55, Iss. 1, pp. 50-50
Open Access | Times Cited: 2
Phahol Sarojvisut, Anucha Apisarnthanarak, Kittiya Jantarathaneewat, et al.
Infection and Chemotherapy (2022) Vol. 55, Iss. 1, pp. 50-50
Open Access | Times Cited: 2
